The EIF3L Knockout HEK293T Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from HEK293T human embryonic kidney cells, designed for loss-of-function studies of the eukaryotic translation initiation factor 3 subunit L (EIF3L). This heterogeneous polyclonal population, generated via CRISPR/Cas9-mediated gene disruption, provides a versatile tool for investigating EIF3L-dependent translational control without clonal selection bias. Given EIF3L’s role in cancer-related translation dysregulation, this model is particularly relevant for oncogenic signaling research.
HEK293T is an adenovirus-transformed human embryonic kidney cell line stably expressing SV40 large T antigen, enabling episomal replication of plasmids containing the SV40 origin and high-efficiency transfection for protein expression, lentiviral packaging, and reporter assays. Its robust growth, well-characterized proteome, and translational activity facilitate quantitative analysis of translation initiation perturbations upon EIF3L knockout.
EIF3L encodes a core subunit of the 13-member eIF3 complex, which orchestrates 43S preinitiation complex assembly and mRNA recruitment to the 40S ribosomal subunit during cap-dependent translation initiation. It interacts directly with multiple eIF3 subunits (eIF3A, eIF3B, eIF3C, eIF3D, eIF3E, eIF3G, eIF3H, eIF3I, eIF3K, eIF3M) and eIF4G, bridging the m7G cap?CeIF4F complex. EIF3L functions downstream of mTORC1, which integrates signals from growth factors, amino acids, and insulin to regulate translation via phosphorylation of 4E-BP1 and S6K1. Consequently, EIF3L loss disrupts eIF3 complex integrity, reducing global protein synthesis and attenuating expression of growth-promoting targets such as cyclin D1 and MYC.
Within HEK293T cells, which sustain high translational output to support rapid proliferation and lentiviral particle production, EIF3L disruption serves as a physiologically relevant model for examining eIF3 complex dependency. The polyclonal knockout population captures heterogeneous editing outcomes, enabling dose-response studies of translation inhibition and dissection of how mTOR?CeIF4F signaling converges on EIF3L to control cell cycle progression and viability.
Researchers can employ this EIF3L polyclonal knockout model in polysome profiling to directly assess translation initiation efficiency, Western blotting to verify EIF3L loss and detect downstream effectors cyclin D1 and MYC, and Click-iT metabolic labeling to quantify de novo protein synthesis rates. mTOR pathway engagement can be interrogated using reporter assays monitoring 4E-BP1 phosphorylation or S6K1 activity. Additionally, the cells are amenable to cell viability and proliferation screens for validating small-molecule translation inhibitors or identifying synthetic lethal interactions relevant to cancer. For further details or to inquire about custom CRISPR-engineered cell services, please contact Ascent Research.
